AcadeMab has initiated a phase I clinical trial at multiple clinical centers, including National Taiwan University Hospital, National Taiwan University Cancer Center, and National Cheng Kung University Hospital.

AcadeMab has initiated a phase I clinical trial at multiple clinical centers, including National Taiwan University Hospital, National Taiwan University Cancer Center, and National Cheng Kung University Hospital. The first subject of this trail has enrolled, and a total of 30 subjects are expected to participate in this clinical trial. Patients enrolled in this trial are with head and neck cancer, colorectal cancer or lung cancer, etc. This clinical study is to investigate the safety, tolerability, pharmacokinetics and preliminary efficacy of AM-928 in patients with advanced solid tumors. Currently, AcadeMab is actively cooperating with US clinical trial centers to accelerate study of AM-928.

AcadeMab is committed to develop new antibody drugs for cancer therapy. Studies have shown that AM-928 can effectively inhibit tumor growth and metastasis through its unique mechanism of action to prevent cleavage of EpCAM. AM-928 also attacks cancer stem cells and significantly prolongs survival rate in animal models, showing the benefit to overcome the current difficulties in cancer therapy. Meanwhile, AM-928 has the potential to treat a variety of cancers since its target protein EpCAM is widely expressed in various cancer cells. In addition, AM-928 has obtained patent protection in important global markets which is competitive among cancer drugs. The initiation of the clinical study is an important step and brings us closer to a potential drug which could improve cancer treatment.